Reboxetine
Small molecule
Evidence outlook · regulatory review
Narcolepsy: application under FDA review, decision date 2027-05-01
FDA accepts AXS-12 NDA (2026-07-15). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
ENCORE (NCT05113745): ENCORE was a randomized, double-blind, placebo-controlled withdrawal study in 68 patients with narcolepsy. Its primary endpoint, cataplexy attack frequency, is a clinical outcome and was met according to the company's announcement; the sources read give no power calculation, so the grade is moderate.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SYMPHONY NCT05059223 · Narcolepsy Study of the molecule, not a specific product SYMPHONY was a 5-week Phase 3, randomized, double-blind, placebo-controlled trial that randomized 90 patients with narcolepsy and cataplexy 1:1 to AXS-12 (reboxetine) or placebo. Its single primary endpoint was the change in weekly cataplexy attacks at Week 5. AXS-12 reduced attacks by 83% against 66% with placebo (p=0.018), so the primary endpoint was met. Registry results are not posted; the figures come from the sponsor's topline release filed with the SEC (Axsome 8-K exhibit 99.1, 25 March 2024). Result from the sponsor's topline release filed with the SEC; no posted registry results or peer-reviewed publication were read. Registry: NCT05059223 | 3 | Frequency of cataplexy attacks (Change from Baseline to Week 5) 2024-03-15 | Weekly cataplexy attacks, change from baseline to Week 5, AXS-12 (reboxetine) vs placebo: reductions of 83% vs 66% (p=0.018); 90 patients randomized 1:1. | not yet graded | link ↗ |
View 1 more trial
ENCORE NCT05113745 · Narcolepsy Study of the molecule, not a specific product ENCORE was a randomized, double-blind, placebo-controlled withdrawal study in 68 patients with narcolepsy. Its primary endpoint, cataplexy attack frequency, is a clinical outcome and was met according to the company's announcement; the sources read give no power calculation, so the grade is moderate. Registry: NCT05113745 | 3 | Long-term safety as measured by the incidence of treatment-emergent adverse events (Up to 28 weeks); Efficacy as measured by change in frequency of cataplexy attacks from baseline. (Baseline to Week 27) 2024-11-15 | Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other norepinephrine transporter drugs
viloxazine, Esreboxetine. Compare all 3 norepinephrine transporter drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Narcolepsy: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Reboxetine: this drug | Phase 3 | Small molecule | norepinephrine transporter | Partial signal | NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26). | |
| Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav) | Approved | Small molecule | GABA-B receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Modafinil (Provigil) | Approved | Small molecule | Sympathomimetic-like Agent | not yet graded | No reviewed efficacy summary in this indication | |
| Oveporexton (Orzeyful) | Approved | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Approved | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Reliable signal | NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) | |
| Sodium Oxybate | Approved | Small molecule | GABA-B receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | Partial signal | NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results). NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label). | |
| Viloxazine (Qelbree) | Approved(overall) | Small molecule | norepinephrine transporter | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Alixorexton | Phase 3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Esreboxetine | Phase 3(overall) | Small molecule | norepinephrine transporter | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Cleminorexton | Phase 2/3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-360 | Phase 2/3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant GR | —(overall) | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Ampreloxetine (TD-9855) | Discontinued | Small molecule | norepinephrine transporter | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent